<DOC>
	<DOCNO>NCT01398280</DOCNO>
	<brief_summary>The purpose study determine effect topical aminocaproic acid immune system assess level antimicrobial peptide skin patient rosacea . It hypothesize aminocaproic acid apply topically alter body 's immune system patient rosacea inhibit activation antimicrobial peptide .</brief_summary>
	<brief_title>Effects Aminocaproic Acid ( ACA ) Rosacea-specific Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Aminocaproic Acid</mesh_term>
	<criteria>Subject male nonpregnant female , 18 70 year age . Subjects willing able give inform consent . Subjects willing able comply requirement study . Subject clinical diagnosis least mild/moderate papulopustular rosacea ( 320 papulopustules ) least mild erythema . Subject stable dose great 3 month medication treatment concurrent medical condition ( include oral contraceptive pill , vasodilator , adrenergic block agent ) OR investigator determine medication unlikely affect patient 's rosacea and/or treatment study Subject general good health opinion investigator . Subject calculated creatinine clearance 100 % normal range . Subject normal baseline labs opinion investigator value clinically significant would inhibit ability monitor patient safety efficacy throughout study . Subject diagnosis Steroid Rosacea Pyoderma Faciale ( rosacea fulminans ) Subject history Carcinoid , Pheochromocytoma , Serotonin Syndrome systemic flushing cause . Subject use facial topical therapy ( OTC drug product prescription product ) reason within prior 28 day Subject use systemic corticosteroid systemic antibiotic ( especially doxycycline , minocycline , tetracycline , metronidazole ) within prior 28 day . Subject laser lightbased treatment rosacea within prior 3 month . Subject systemic retinoids retinoid derivative past 6 month Subject active recent history coagulation ( hyper hypo ) disorder , genitourinary bleeding , myopathy , cardiomyopathy , rhabdomyolysis evidence clinically significant hepatic disease opinion investigator , Subject take medicines supplement interfere blood clot Coumadin , Plavix , ASA ( &gt; 81mg/day ) . Subject know hypersensitivity allergy aminocaproic acid component vehicle . Subject pregnant lactating planning pregnancy duration study Subject treat another investigational device drug within 28 day prior study enrollment intend participate clinical trial concurrent study Subject clinically significant finding , medical history condition ( rosacea ) , opinion Investigator may compromise study , treatment protocol , safety patient treatment allocation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Rosacea</keyword>
	<keyword>Dermatology</keyword>
	<keyword>UCSD</keyword>
	<keyword>Skin disease</keyword>
</DOC>